Hussein Sweiti's departure as Chief Medical Officer of enGene Therapeutics Inc. was reported, effective June 14, 2026; the filing names no successor. As of November 6, 2026, enGene Therapeutics Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 15, 2026 to July 16, 2026, naming 2 departures (Form 8-K, June 15, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like enGene Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
enGene Therapeutics Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-15 to 2026-07-16. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as enGene Therapeutics Inc. files it.
Layoffs on record: 2 filings or notices, latest 2026-06-18 (layoff filings and notices).
Also on the record for enGene Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | — | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Raymond Debbane | 9.3% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by Blue Owl Capital Holdings LP | 0.76% of the class | 5%+ stakes | Source |
| July 22, 2026 | Stake report, Schedule 13G, by Anders Hove | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | — | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by BML Investment Partners, L.P. | 9.95% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G, by BML Investment Partners, L.P. | 7.8% of the class | 5%+ stakes | Source |
| May 5, 2026 | Stake report, Schedule 13G/A, by Raymond Debbane | 7.8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Cormorant Asset Management, LP | 5.97% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Kynam Capital Management, LP | 2.23% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs enGene Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on enGene Therapeutics Inc. and the records around it.
enGene Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Jun 2026
- Who owns it
Companies that share a holder
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), Athira Pharma, Inc. (Aug 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026), ImageneBio, Inc. (May 2026)
Watch enGene Therapeutics Inc.
Get an email when enGene Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on enGene Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on enGene Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on enGene Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-16 | Out | Director | 8-K, 2026-07-16 | ||
| 2026-06-15 | Out | Chief Medical Officer | 2026-06-14 | 8-K, 2026-06-15 |
Who leads enGene Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Richard Glickman, departure reported (filed 2026-07-16). No successor is named in these filings.
- Chief Medical Officer: Hussein Sweiti, departure reported, effective 2026-06-14 (filed 2026-06-15). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on enGene Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at enGene Therapeutics Inc., with the record behind each one.
Find candidates like Director at enGene Therapeutics Inc.Every change, in the filing's words
Departing: Richard Glickman, Director
On July 15, 2026, Dr. Richard Glickman resigned as a director and chairman of the Board of Directors (the "Board") of enGene Therapeutics Inc. (the "Company"), including as a member of any committee of the Board.
- Dr. Glickman first notified the Company of his resignation July 15, 2026, and his resignation became effective immediately.
- Dr. Glickman's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Board thanks Dr. Glickman for his contributions and many years of dedicated service to the Company.
Departing: Hussein Sweiti, Chief Medical Officer, effective 2026-06-14
On June 13, 2026, Dr. Hussein Sweiti notified the Company of his resignation from his position as Chief Medical Officer and Head of Research and Development of the Company, with his resignation to be effective as of June 14, 2026.
Tools for this story
Each opens in a new tab, filled in for enGene Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.